FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration

뉴스 본문을 불러오고 있어요.

FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration | 웨이프 WAPE

FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration

기사 요약

관련 종목

댓글 —